InvestorsHub Logo
Followers 25
Posts 1133
Boards Moderated 0
Alias Born 04/04/2012

Re: The Bread Man post# 12388

Monday, 11/17/2014 9:12:52 AM

Monday, November 17, 2014 9:12:52 AM

Post# of 15766
Canaccord Genuity Initiates Mast Therapeutics With Buy, $3.00


8:40a ET November 17, 2014 (Benzinga)

Analysts at Canaccord Genuity initiated coverage on shares of Mast Therapeutics (NYSE: MSTX) with a Buy rating.

The target price for Mast Therapeutics is set to $3.

Mast Therapeutics' shares jumped 11.11% to $0.50 in pre-market trading.

Latest Ratings for MSTX DateFirmActionFromTo

Nov 2014Canaccord GenuityInitiates Coverage onBuy Oct 2013Canaccord GenuityInitiates Coverage onBuy

View More Analyst Ratings for MSTX
View the Latest Analyst Ratings